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Abstract
Background: Secreted protein acidic and rich in cysteine (SPARC) plays a key role in the development of many tissues 
and organ types. Aberrant SPARC expression was found in a wide variety of human cancers, contributes to tumor 
development. Because SPARC was found to be overexpressed in human gastric cancer tissue, we therefore to explore 
the expression of SPARC in gastric cancer lines and the carcinogenic mechanisms.
Methods: SPARC expression was evaluated in a panel of human gastric cancer cell lines. MGC803 and HGC 27 gastric 
cancer cell lines expressing high level of SPARC were transiently transfected with SPARC-specific small interfering RNAs 
and subsequently evaluated for effects on invasion and proliferation.
Results: Small interfering RNA-mediated knockdown of SPARC in MGC803 and HGC 27 gastric cancer cells dramatically 
decreased their invasion. Knockdown of SPARC was also observed to significantly increase the apoptosis of MGC803 
and HGC 27 gastric cancer cells compared with control transfected group.
Conclusions: Our data showed that downregulating of SPARC inhibits invasion and growth of human gastric cancer 
cells. Thus, targeting of SPARC could be an effective therapeutic approach against gastric cancer.
Introduction
Gastric cancer is the second leading cause of cancer-
related deaths worldwide and is one of the most aggres-
sive tumors and is frequently associated with lymph node
metastasis, peritoneal dissemination, and hematogenous
metastasis[1]. On the whole, 65-70% of new cases and
deaths from gastric cancer occur in less-developed coun-
tries[2]. In 2005, the incidence rates of gastric cancer (0.3
million deaths and 0.4 million new cases) ranked third
among the most common cancers in China[3]. Current
therapies for advanced stage or metastatic gastric cancer
have little effect, surgical removal with resection of adja-
cent lymph nodes offers the only chance for cure, which is
less than 33% of patients with gastric cancer. The 5-year
survival rate is only 30-40%, with a poorer prognosis for
advanced tumours. Understanding the molecular mecha-
nisms underlying the progression of gastric cancer may
provide insights into new therapeutic targets.
Secreted protein acidic and rich in cysteine (SPARC;
also known as osteonectin or BM-40) belongs to the
matricellular family of secreted proteins[4]. SPARC is a
nonstructural component of extracellular matrices that
modulates cell-matrix interactions, particularly during
tissue development, remodeling and repair[5]. Many
types of cancers are characterized by upregulated expres-
sion of SPARC[6]. Overexpression of SPARC has been
documented in several types of solid tumors, such as
breast[7], prostate[8], melanoma[9] and glioblasto-
mas[10]. In contrast, lower levels of SPARC expression
have been found in other types of cancers, such as ovar-
ian[11], colorectal[12], pancreatic[13,14] and acute myel-
ogenous leukemia[15]. These observations suggest that
tumorigenic effect of SPARC is cell type specific and may
be dependent of the tumor cell surrounding environ-
ment.
The knowledge about SPARC functions in gastric can-
cer cells is still sparse. Overexpression of the SPARC gene
was observed in human gastric cancer in five other
reports[16-20]. However, all above-mentioned studies
had no detail in gastric cancer cell lines and carcinogenic
mechanism. SPARC has been associated with aggressive
stages of gastric cancer and is correlated with poor prog-
nosis[16], which suggests that the reduction of SPARC
expression may have therapeutic benefit. Indeed, expres-
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sion of antisense oligonucleotides against SPARC in mel-
anoma cells blocked tumor formation[21]. The precise
biological and molecular mechanisms through which a
reduction in SPARC expression might contribute to
improved tumor therapy remain to be investigated.
Therefore, the aim of the present study was to character-




Human gastric cancer cell lines NCI-N87, SGC7901,
MGC803, BGC823, HGC27 were obtained from the Can-
cer Institute of Chinese Academy of Medical Science. All
cells were grown in RMPI 1640 (GIBCO™)medium sup-
plemented with 10% fetal bovine serum, penicillin G (100
units/ml), and streptomycin (100 μg/ml) termed com-
plete medium. Cells were maintained in monolayer cul-
ture at 37°C in humidified air with 5% CO2.
Chemicals and reagents
EDTA-2 sodium, acridine orange, ethidium bromide (EB)
and 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazoli-
umbromide (MTT) were purchased from Sigma (St
Louis, MO, USA). Mouse monoclonal antibody specific
to β-actin was from Sigma. Rabbit polyclonal antibodies
specific to Bcl-2 (sc-492), caspase-3 (sc-7148) and PARP
(sc-7150) were bought from Santa Cruz Biotechnology
(Santa Cruz, CA, USA). Mouse monoclonal antibodies
specific to SPARC(sc-74295) and Bax (sc-7480) were
obtained from Santa Cruz Biotechnology. Goat anti-rab-
bit (w3960) and anti-mouse (w3950) secondary antibod-
ies were purchased from Promega (Madison, WI, USA).
RNAi and transfection
Human SPARC siRNA and control siRNA were from
Dharmacon Bioscience Corp (Chicago, IL, USA).
Equimolar amounts of siRNAs were used as per the man-
ufacturer's instructions with control non-targeting
siRNA (CTRL). 150 000 cells were plated per six-well in
DMEM with 10% FBS and were allowed to attach over-
night. Equimolar amounts of siRNAs were incubated
with TransIT-TKO Transfection Reagent from Mirus
(Madison, WI, USA) as per the manufacturer's instruc-
tions. Cells were maintained for 48 h before experiments,
unless otherwise described
Western blot analysis
Twenty micrograms of total proteins were separated by
SDS-PAGE and transferred onto a PVDF membrane. The
membrane was then incubated with antibodies specific
for SPARC (Santa Cruz; 1:500), or anti-β-actin (Sigma;
1:1,000) overnight at 4°C. Bound antibodies were visual-
ized using enhanced chemiluminescence. To confirm
equal loading, membranes were stripped for 30 minutes
at 50°C in buffer containing 2% SDS, 62.5 mM Tris (PH
6.7), and 100 mM 2-mercaptoethanol and reprobed with
an anti-β-actin antibody to demonstrate equal loading.
The density of the bands was quantified by densitometric
analysis using the ImageTool (version 3.0) system.
RT-PCR
Total RNA (1-2 μg) was reverse transcribed using a
SuperScript pre-amplification kit (Invitrogen, Carlsbad,
CA). Primers were based on sequences reported on Gen-
ebank (NM 003118). SPARC sense sequence was 5'-GTG-
GGCAAAGGGAAGTAACA-3' and SPARC anti-sense
sequence 5'-GGGAGGGTGAAGAAAAGGAG-3'. The
expected product size of SPARC cDNA was 512bp. ß-
actin sense sequence was 5'-GGCATCCTCACCCT-
GAAGTA-3' and ß-actin anti-sense sequence 5'-
GTCAGG CAGCTCGTAGCTCT-3'. The expected
product size of ß-actin cDNA was 514bp. PCR amplifica-
tion was performed in 25 μl reaction volumes containing
0.2 μM dNTPs, 20 pmol of each oligonucleotide primer,
and 0.2U Tag polymerase in PCR buffer. cDNA was
amplified on a PCR thermal controller with an initial
denaturation at 95°C for 5 min, followed by cycles of 95°C
for 1 min, 65°C for 1 min, and 72°C for 1 min, 27 cycles,
and a final extension step of 72°C for 10 min. The amount
of starting cDNA was adjusted using β-actin intensity.
Cell migration assay
The ability of cells to migrate through filters was mea-
sured using a BioCoat Matrigel invasion chamber (BD
Biosciences, San Jose, CA). Cell culture inserts with an 8
μm pore size PET membrane were used according to the
protocol of the manufacturer. The bottom chamber
included medium (0.75 ml) containing 10% FCS, whereas
SPARC siRNA transfected or control transfected cells
(1.0 × 105 suspended in 0.5 mL of medium containing 1%
FCS) were seeded into the upper chamber and incubated
overnight at 37°C in a humidified atmosphere containing
5% CO2. Remaning cells on the upper surface were
mechanically removed. Membranes were then washed,
fixed, and stained by Diff-Quik (Medion Diagnostics).
The number of cells that migrated to the lower surface of
the filters was determined by counting stained cells under
a light microscope in three independent fields (0.25 mm2/
well).
Cell growth and viability assay
The effect of SPARC SiRNA on the viability of cells was
determined by the MTT assay. Briefly, MGC803 and
HGC 27 cells were plated at 1 × 104 cells per well in
ninety-six-well microtitre plates. After incubation for 72
h, cell viability was determined. Then 20 μl MTT (10 mg/
ml in PBS stock, diluted to working concentration of 1Yin et al. Journal of Experimental & Clinical Cancer Research 2010, 29:59
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mg/ml with media) was added to each well and incubated
for 4 h. After careful removal of the medium, 200 μl dim-
ethyl sulfoxide was added to each well and shaken care-
fully. The absorbance was recorded on the microplate
reader (ELX 800; Bio-Tek Instruments, Inc. Winooski,
VT, USA) at a 570 nm wavelength. The effect of SPARC
siRNA on cell growth inhibition was assessed as percent-
age cell viability where vehicle treated cells were taken as
100% viable.
Cell cycle analysis and annexin V staining
For flow cytometric cell cycle analysis, the cells treated
with siRNA were collected, washed with PBS, fixed in
cold 70% ethanol, and stored at -20°C until staining. After
fixation, the cells were washed with PBS and incubated
with 50 μg ⁄mL RNaseA (Sigma) for 30 min at 37°C, before
staining with 50 μg ⁄mL propidium iodide (Sigma). Apop-
totic cells in early and late stages were detected using an
annexin V-FITC Apoptosis Detection Kit from BioVision
(Mountain View, CA, USA). In brief, the cells were trans-
fected with siRNA. At 96 h post-transfection, culture
media and cells were collected and centrifuged. After
washing, cells were resuspended in 490 μL annexin V
binding buffer, followed by the addition of 5 μL annexin
V-FITC and 5 μL propidium iodide. The samples were
incubated in the dark for 5 min at room temperature and
analyzed using flow cytometry.
Statistics
Results were expressed as mean expression levels (± SD).
Student's t-test or rank sum test were used for statistical
analysis. A p-value < 0.05 was taken as level of signifi-
cance (two-sided).
Results
Expression of SPARC in cultured gastric cancer cells
We first evaluated the endogenous expression of SPARC
in several human gastric cancer cell lines. We found that
SPARC protein and mRNA were prevalent in MGC803
a n d  H G C 2 7  c e l l s ,  w e r e  p r o d u c e d  a t  l o w e r  l e v e l s  b y
SGC7901 cell line were undectable in NCI-N87 and
BGC823 cell lines(Figure 1).
Inhibition of endogenous SPARC expression
Following this initial screening, MGC803 cells and
HGC27 cells expressing relatively high endogenous
SPARC were established knockdown expressing SPARC
in a transient manner to determine the importance of
endogenous SPARC expression. As shown in Figure 2A,
SPARC expression was inhibited with SPARC siRNA
transfectants in protein levels. These results suggest that
these SPARC siRNAs successfully exert a silencing effect
for SPARC expression.
Downregulation of SPARC expression inhibited gastric 
cancer cells invasion in vitro
To determine if SPARC siRNA could reduce protumori-
genic cellular behaviors associated with SPARC expres-
sion, we first determined the effect of decreased SPARC
expression on tumor cell invasion. Cell invasion assay
were then performed using Transwell chambers. We
measured the capacity of gastric cancer cells to invade
through Matrigel, an artificial extracellular matrix, after
transfection with a non-targeting control siRNA or
SPARC siRNA. Decreased SPARC expression led to the
inhibition of invasion by 69% and 79% in MGC803 and
HGC27, respectively (Figure 2B, C). Taken together, these
results clearly indicate that suppression of SPARC inhib-
Figure 1 Expression of SPARC in gastric cancer cell lines. A, Immu-
noblot analysis using a rabbit polyclonal SPARC antibody (1:500). B, 
Specific reverse transcriptase polymerase chain reaction (RT-PCR) anal-
ysis for SPARC. β-actin was used as loading control. C, Relative SPARC 
mRNA expression levels. Autoradiographs were scanned and analyzed 
by densitometry followed by quantitation relative to β-actin. Results 
are shown as expression (in %) relative to β-actin and are means (± SD) 
of 3 experiments.Yin et al. Journal of Experimental & Clinical Cancer Research 2010, 29:59
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its the migration and invasion ability of MGC803 cells
and HGC27 cells.
Downregulation of SPARC expression inhibits growth of 
gastric cancer cells in vitro
We investigated whether SPARC siRNA could decrease
the survival of gastric cancer cells. MGC 803 and HGC 27
gastric cancer cells transfected with SPARC siRNA sur-
vived at decreased rates relative to matched cells trans-
fected with a non-targeting control siRNA (Figure 3A).
Downregulation of SPARC expression didn't induce cell
cycle arrest in gastric cancer cells. We examined the
effects of SPARC siRNA on cell cycle progression. Silenc-
ing of SPARC in MGC803 and HGC27 cells didn't change
G1 or S phase populations at 72 h posttransfection with
SPARC siRNA in comparison with the negative control
group(Figure 3B).
Inhibition of SPARC expression enhances apoptosis in 
gastric cancer cells
We investigated whether SPARC siRNA could induce cell
death in gastric cancer cell lines. The treatment of
MGC803 and HGC27 cells with SPARC siRNA increased
early apoptotic cells as well as late apoptotic cells, com-
pared with negative control siRNA treatment (Figure 4A)
as measured by the Annexin V assay. As expected, the
decreased survival of the cells transfected with SPARC
siRNA was associated with increased rates of apoptosis
by 91% in MGC803 and 92% in HGC27 cells (Figure 4B).
These findings suggest that SPARC is involved in apopto-
sis to maintain cellular survival in some gastric cancer
cells.
Apoptotic effect of SPARC siRNA transfected treatment in 
MGC 803 and HGC27 cells
In an effort to elucidate the mechanism of SPARC siRNA
induced apoptosis in MGC 803 cells and HGC27 cells,
expression levels of apoptotic-regulation proteins such as
Bcl-2, Bax and caspase-3 and PARP were evaluated. MGC
803 cells and HGC27 cells were transfected with SPARC
siRNA. As shown in Figure 5, There were significant dif-
ferences in the expressions of Bax and Bcl-2 in MGC 803
cells and HGC27 cells in comparison with the negative
control group (P < 0.05 and P < 0.01). In response to
apoptotic stimuli, procaspase-3 is cleaved into a 20 kDa
fragment, and the subsequent autocatalytic reaction leads
to the formation of the active 17 kDa fragment. When the
caspase-3 is activated, PARP is cleaved. Thus cleavage of
P ARP is used as an indicator of apoptosis. In order to
obtain direct evidence showing the relationship of cas-
pase activation and apoptosis, procaspase-3 cleavage and
PARP were examined in MGC 803 cells and HGC27 cells
after SPARC siRNA transfected. As shown in Figure 5,
SPARC SiRNA induced the cleavage of 32 kDa procas-
pase-3 into its active 17 kDa form and cleavage of PARP
appeared in MGC 803 cells and HGC27 cells.
Discussion
Secreted protein and rich in cysteine, SPARC (also known
as osteonectin; or basement-membrane-40, BM-40), is a
member of a family of matricellular proteins, whose func-
tion is to modulate cell-matrix interactions and cell func-
tion without participating in the structural scaffold of the
extracellular matrix. Overexpression of SPARC has been
documented in several types of solid tumors, such as
breast[7], prostate[8], melanoma[9] and glioblasto-
mas[10]. In contrast, lower levels of SPARC expression
have been found in other types of cancers, such as ovar-
ian[11], colorectal[12], pancreatic[13,14] and acute myel-
ogenous leukemia[15]. These observations suggest that
tumorigenic effect of SPARC is cell type specific and may
Figure 2 Effect of SPARC knockdown on cell migration in gastric 
cancer cell lines MGC 803 and HGC 27 cells. A. SPARC expression in 
MGC 803 and HGC 27, control and SPARC siRNA transfected cells was 
detected by immunoblot analysis using a rabbit polyclonal SPARC an-
tibody (1:500). β-actin was used as loading control. B. Effects of SPARC 
knockdown on cell migration in gastric cancer cell lines. SPARC expres-
sion was knocked down in MGC 803 and HGC 27 cells using SPARC siR-
NA and subjected to a migration assay using a two-chambered 
invasion apparatus as described in Materials and Methods, histogram 
showing percent inhibition of MGC 803 and HGC 27 cell invasion. The 
experiment was done in triplicate and the value obtained from scram-
bled siRNA transfected cells was set as 100%.Yin et al. Journal of Experimental & Clinical Cancer Research 2010, 29:59
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Figure 3 Effects of SPARC knockdown on cell growth in gastric cancer cell lines. the left half data represent data obtained from MGC 803 cells 
and the right ones represent data obtained from HGC 27 cells. A. Basal growth was determined after 48 h in complete medium by the MTT assay. 
Results are shown as mean growth (in %) of the respective MGC 803 and HGC 27 cell line and are means (± SE) of quadruplicate determinations from 
six separate experiments. Cells from the siRNA and control groups were collected for cytometry cell cycle analysis. B. Silencing of SPARC by siRNA trans-
fection did not change cell cycle distribution in MGC 803 and HGC 27 gastric cancer cells. MGC 803 and HGC 27 cells were transfected with SPARC 
siRNA or negative control siRNA. At 72 h post-transfection, DNA content was measured using propidium iodide (PI) staining on flow cytometry.Yin et al. Journal of Experimental & Clinical Cancer Research 2010, 29:59
http://www.jeccr.com/content/29/1/59
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Figure 4 SPARC knockdown results in induction of apoptosis in gastric cancer cell lines. For flow cytometric analysis, cells were harvested 96 h 
after transfection with SPARC siRNA or negative control siRNA, then stained with annexin V-FITC and propidium iodide (PI). the left half data represent 
data obtained from MGC 803 cells and the right ones represent data obtained from HGC 27 cells. The percentages of annexin V/PI(early apoptotic) 
and annexin V/PI(late apoptotic) cells is shown in each panel. Values in bold indicate decreasing SPARC expression increased apoptosis by 65% in 
MGC803 and 92% in HGC27 compared with negative control siRNA.Yin et al. Journal of Experimental & Clinical Cancer Research 2010, 29:59
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be dependent of the tumor cell surrounding environ-
ment.
The knowledge about SPARC functions in gastric can-
cer cells is still sparse. Some immunohistochemical stud-
ies[16-20,22] collectively reported an up-regulation of
SPARC in gastric cancer compared with nonneoplastic
mucosa. Wewer et al.[17] described a differential expres-
sion of SPARC in the epithelial and stromal compart-
ments of six gastric cancer specimens. Maeng[18] found
that SPARC is highly expressed in reactive stroma associ-
ated with invasive differentiated adenocarcinomas and
that it may serve as a useful clinical diagnostic marker for
stomach cancer. Wang et al.[16] also found a differentially
expressed SPARC in gastric cancer patients as assessed by
gene array analysis, quantitative RT-PCR, and immunos-
taining, higher SPARC expression was significantly asso-
ciated with tumour progression and the advanced stages
of gastric cancer. Franke et al.[20] demonstrated on a
larger patient series that SPARC is differentially
expressed in gastric cancers and that its expression corre-
lates with tumor progression and nodal spread using tis-
sue microarrays (TMAs), The level of expression of
SPARC, determined by immunohistochemistry, corre-
lated in intestinal-type gastric cancer with the local
tumor growth, nodal spread, and tumor stage according
to the International Union Against Cancer. Zhao ZS et
al.[19] found that SPARC was detected in 334 of 436
human gastric cancer cases and was highly expressed in
239 tumors. In stages I, II, and III, the 5-year survival rate
of patients with a high expression of SPARC was signifi-
cantly lower than those in patients with low expression.
Further multivariate analysis suggested that upregulation
of SPARC, MMP-2, and integrin beta1, were independent
prognostic indicators for the disease.
We have Collected 49 gastric cancer tissues and corre-
sponding normal tissues through surgical procedures(Jie
Yin, Guowei Chen, Si Liu, Jianxun Zhao, Yucun Liu:
Expression of SPARC in human gastric cancer is associ-
ated with the clinical-pathological features, submitted).
The distribution and expression of SPARC were observed
by immunohistochemistry, Western Blotting and RT-
PCR, respectively. SPARC protein and mRNA expressed
significantly higher in gastric cancer tissues compared to
normal tissues. The degrees of its expression were associ-
ated with differentiation of tumor, TNM division, perito-
neal seeding and vascular invasion remarkably. Patients
w i t h  h i g h  e x p r e s s i o n  o f  S P A R C  h a v e  w o r s e  p r o g n o s i s
than those with low expression of SPARC.
Taken together, higher SPARC expression was signifi-
cantly associated with tumour progression and advanced
stages of gastric cancer. Recent research of Inoue M et
al[23] even identifed SPARC as a candidate target antigen
for immunotherapy of various cancers including gastric
cancer by genome-wide cDNA microarray. It is exciting
that therapy targeting the SPARC subunit may be a useful
approach to suppress gastric cancer growth. However, the
molecular mechanisms responsible for the oncogenesis of
SPARC in gastric cancer is not entirely understood.
Through expression analysis of a panel of gastric cancer
cell lines, we showed that SPARC is also overexpressed in
sevel human gastric cancer cell lines. Therefore, we tested
our hypotheses that SPARC may be a key molecule in
gastric cancer invasion, and that targeting SPARC may
present a novel therapeutic strategy for anti-invasion of
gastric cancer.
Dissemination of cancer cells, either locally or at dis-
tant metastatic sites, requires that malignant cells acquire
the ability to invade the basement membrane and to
adhere to other matrices. It has been suggested that
SPARC may play a key role during the initial steps in the
process of tumour invasion and metastasis[24]. In addi-
tion, SPARC can induce the expression of metalloprotei-
nases or enzymes that subsequently play an important
role in the degradation of basal membranes and extracel-
lular matrix components[25]. SPARC was associated with
the invasiveness of meningiomas[26,27] and gliomas[28].
Furthermore, suppression of SPARC expression using
antisense RNA inhibited motility and invasion of human
breast cancer cells in vitro[21].
Figure 5 The expression of apoptosis proteins in MGC 803 and 
HGC27 cells after transfection with either control or SPARC siRNA. 
The cell lysates were separated on 10% SDS-PAGE gel, transferred to ni-
trocellulose membrane and probed with anti-PARP, anti-caspase-3, 
anti-Bcl-2, and anti-Bax. Protein contents were normalized by probing 
the same membrane with anti-β-actin. The left half data represent data 
obtained from MGC 803 cells and the right ones represent data ob-
tained from HGC 27 cells.Yin et al. Journal of Experimental & Clinical Cancer Research 2010, 29:59
http://www.jeccr.com/content/29/1/59
Page 8 of 9
To determine if SPARC siRNA could reduce protum-
origenic cellular behaviors associated with SPARC
expression, we first determined the effect of decreased
SPARC expression on tumor cell invasion. We measured
the capacity of gastric cancer cells to invade through
Matrigel, an artificial extracellular matrix, after transfec-
tion with SPARC siRNA or a non-targeting control
siRNA. Decreased SPARC expression led to the inhibi-
tion of invasion by 69% and 79% in MGC803 and HGC27,
respectively. Thus, SPARC siRNA can decrease gastric
cancer invasion in vitro.
A recent study found that SPARC protects cells from
stress-induced apoptosis in vitro through an interaction
with integrin β1 heterodimers that enhance ILK activa-
tion and prosurvival activity[28]. Initial studies using
antisense RNA strategies completely abrogated human
melanoma growth in nude mice[21]. Horie et al.[29]
showed that the downregulation of SPARC expression
induced growth inhibition with G1 arrest in human mela-
noma cells. It has been reported that SP ARC promotes
glioma cell survival through Akt activation through integ-
rin signaling under serum-free conditions [30]. These
reports strongly suggest that SPARC plays a role as an
antistress factor.
On the other hand, some articles found that SPARC
may promote apoptosis in cancer cells. Yiu and col-
leagues[11] showed that exogenous treatment of various
ovarian cancer cell lines with SPARC induced apoptosis.
Said and Motamed[31] found SPARC exposure increased
cleaved caspase 3 in human ovarian carcinoma cells
which supported the former observation. Pancreatic[13]
and ovarian cancers[30] exhibited greater growth and
reduced apoptosis when implanted in SPARC-/-. In col-
orectal cancer cell lines, overexpression of SPARC
reduced cell viability and enhanced apoptosis in cells
exposed to various chemotherapeutic agents[32].
These seemingly paradoxical observations within each
type of cancer and across different cancers can be
explained by Tai's understanding of SPARC biology[33]:
smaller peptide fragments of SPARC representing the dif-
ferent domains of SPARC confer biological activities
which at times, oppose those of other fragments or the
native SPARC protein. Since the protease profile of the
tumor microenvironment may differ in different types of
cancers, and as SPARC is known to undergo proteolysis
by matrix metalloproteinases[34], these differences, in
combination with changes in the local composition of
matrix molecules and cytokines, may all be contributing
to the complex behavior of SPARC in different types of
cancer.
To elucidate the effects of SPARC siRNA on gastric
cancer cell growth, MTT proliferation assay was per-
formed to compare the proliferation between SPARC
siRNA transfected and control transfected MGC803 and
HGC 27 cells. MGC803 and HGC27 gastric cancer cells
transfected with SPARC siRNA survived at decreased
rates relative to matched cells transfected with a non-tar-
geting control siRNA (Figure 3). The decreased survival
of the cells transfected with SPARC siRNA was associated
with increased rates of apoptosis as measured by the
Annexin V assay. Decreasing SPARC expression
increased apoptosis by 91% in MGC803 and 92% in
HGC27 (Figure 4B).
Active caspases play an important role in the induction
o f  a p o p t o s i s .  W h e n  c a s p a s e - 3  w a s  a c t i v a t e d ,  P A R P  i s
cleaved late. Usually the cleavage of PARP was used as an
indicator of apoptosis. In the present study, we found
SPARC siRNA activated caspase-3 to produce cleaved
caspase-3 (p17) fragments in MGC 803 cells and HGC 27
at 48 h. At the same time, the cleavage of PARP was also
detected. The results indicate that SPARC induced frag-
mentation of PARP as well as increased caspase-3 activity
in MGC 803 cells.
The Bcl-2 family proteins have been reported to regu-
late apoptosis by controlling the mitochondrial mem-
brane permeability. SPARC up regulated the expression
of Bax and down regulated the expression of Bcl-2 in
MGC 803 cells and HGC 27 cells. We found that SPARC
siRNA could induce gastric cancer cell apoptosis and
simultaneously reduce the ratio of Bcl-2 to Bax. There-
fore, the regulation of Bcl-2 and Bax expression may be a
key mechanism underlying SPARC induction of apopto-
sis in gastric cancer cells.
So our data indicated that downregulation of SPARC
inhibited cell proliferation of gastric cancer cells by apop-
tosis initiation, which conscience with melanoma and
glioma, but contrary to ovarian and pancreatic cancer.
The induction of apoptosis was partly regulated to mito-
chondrial pathway such as activation caspase pathway as
well as cleavage of PARP. Future study needs to focus on
the exact mechanism.
In conclusion, our current data suggested that SPARC
played important roles in apoptosis and metastasis of
gastric cancer. At present, there are no effective
approaches for curing late stage gastric cancer. As ele-
vated SPARC expression is associated with decreased
gastric cancer patient survival[16], we believe that our
results, demonstrating decreased invasion and increased
cell death with siRNA directed against SPARC, suggest
that decreasing SPARC expression may have therapeutic
benefit for gastric cancer patients.
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